Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by KalVista Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 Next >

KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

January 05, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 04, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering

December 27, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

December 08, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

November 14, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

November 07, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 02, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

October 31, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat

October 19, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman

October 17, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

October 07, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

October 04, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop

September 30, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports First Fiscal Quarter Results

September 08, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

August 23, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 02, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference

July 19, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

July 07, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program

July 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)

June 23, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program

June 08, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 03, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference

June 01, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Changes to Board of Directors

May 27, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900

May 17, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference

April 11, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by KalVista Pharmaceuticals, Inc.

Starting at $3.75/week.

Subscribe Today